Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the 311 Institute, a global futures and deep futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future.” Regularly featured in the global media, including AP, BBC, CNBC, Discovery, RT, and Viacom, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Bain & Co, BCG, BOA, Blackrock, Bentley, Credit Suisse, Dell EMC, Dentons, Deloitte, Du Pont, E&Y, GEMS, HPE, Huawei, JPMorgan Chase, KPMG, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, UBS, and many more.
WHY THIS MATTERS IN BRIEF
Up until know hospitals have had to run multiple tests to identify multiple pathogens, which takes time and can cost lives, now they just need one.
Imagine being able to use one test to screen for every type of known and unknown human disease with just one test. Well, now scientists at the Center for Infection and Immunity (CII) in the Columbia University Mailman School of Public Health in the US have developed one and it’s the first diagnostic platform that can simultaneously screen for all known human pathogenic bacteria as well as markers for virulence and antibiotic resistance, and as the number of pandemics, for example, the recent Ebola outbreak in Africa increase, being able to identify the pathogens involved in the outbreaks quickly in order to save lives is of increasing importance. In fact time is such an important factor that DARPA, the US bleeding edge military research organisation, unveiled a program February last year known as the P3 program that aims to identify and stop pandemics in their tracks within just 60 days.
“Once approved for clinical use, BacCapSeq will give physicians around the world a powerful tool to quickly and precisely screen for all known pathogenic bacteria, including those that cause sepsis, the third leading cause of death in the United States,” says first author Orchid Allicock, Ph.D., a post-doctoral researcher at CII. “This platform is 1,000 times more sensitive than traditional unbiased testing, at a level comparable to tests that screen one bacterium at a time.”
Currently, the most common method used to test for sepsis, for example, can take as long as three days, and even longer to provide information on antibiotic resistance. While physicians wait for a result, they usually prescribe broad spectrum antibiotics, a practice that contributes to the growth of antibiotic resistance. Meanwhile BacCapSeq provides results in 70 hours, but the researchers believe that the platform will become faster with future advances in computing power.
Each year, antibiotic-resistant infections claim 100,000 lives in the US, and 700,000 globally, with the highest burden in the developing world, according to World Economic Forum estimates. The direct annual impact of antibiotic resistance in the US alone is estimated at between $20 and 35 billion with an additional $35 billion in lost productivity, according to the US Center for Disease Control and Prevention. Absent an effective response to limit further growth in antimicrobial resistance, the challenge will continue to increase. The World Bank issued a report in 2017 projecting an impact on the GDP between $1.1 trillion and $3.4 trillion.
BacCapSeq contains 4.2 million genetic probes used to detect the signature DNA of all 307 pathogenic bacteria, as well as biomarkers for antibiotic resistance and virulence. Each probe binds to a corresponding sequence – when a particular bacterium and biomarker is present in a sample, a magnetic process “pulls out” its unique sequences, which can then be used to identify the bacterium and its characteristics. To date, even the most advanced multiplexed polymerase chain reaction systems are only able to screen for up to 19 pathogenic bacteria, and none can assess virulence and antimicrobial resistance.
In the study, the researchers assess the performance of BacCapSeq in several ways, such as using nucleic acid from blood spiked with DNA from several different bacteria, blood spiked with bacterial cells, blood culture samples, and blood samples from patients with unexplained illnesses. In each case, the platform performance exceeded traditional methods, sometimes detecting infections that were missed by the alternative method. In one case, the test implicated the bacterium Gardnerella vaginalis, which is only rarely associated with significant disease, as the cause of unexplained sepsis in an individual with HIV.
BacCapSeq is a complement to VirCapSeq, a similar test developed at CII that screens for all known human viral infections. Recent published studies have reported on that test’s performance in Tanzania and Uganda. A test for differential diagnosis of fungal infections is in development.
“Microbiological intelligence must be an integral component of precision medicine,”says Ian Lipkin, MD, director of CII and the John Snow Professor of Epidemiology at Columbia Public Health. “Accurate, early differential diagnosis of infectious diseases and knowledge of drug sensitivity profiles will all help reduce mortality, morbidity, and health care costs.”
A study in the journal mBio provides details on the performance of the BacCapSeq platform.